Health Care Reform
September 28, 2009

Weighing the Benefits and Downsides of Prostate-Specific Antigen Screening

Author Affiliations

Copyright 2009 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2009

Arch Intern Med. 2009;169(17):1554-1556. doi:10.1001/archinternmed.2009.269

Prostate cancer is common (186 000 new US diagnoses in 2008), causing more than 28 000 deaths per year.1 Treatment of clinically detected prostate cancer is effective in reducing prostate cancer mortality in men younger than 65 years but not in older men.2 However, treatment of prostate cancer is associated with considerable morbidity; approximately 50% of men will have impotence, incontinence, or both after treatment, and a few will die as a result of initial treatment.3

First Page Preview View Large
First page PDF preview
First page PDF preview